Ken Griffin Candel Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 85,000 shares of CADL stock, worth $675,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,000
Previous 60,200
41.2%
Holding current value
$675,750
Previous $373,000
57.91%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CADL
# of Institutions
56Shares Held
6.41MCall Options Held
109KPut Options Held
130K-
Northpond Ventures, LLC1.94MShares$15.4 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$7.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$6.54 Million0.0% of portfolio
-
State Street Corp Boston, MA492KShares$3.91 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$3.57 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $230M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...